why choose us

First received: September 04, 2024

Clinical Trial: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Psoriasis
Obesity

Study Type: INTERVENTIONAL


Official Title: Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight: A Phase 3b, Random

Brief Summary: The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriasis and achieve weight reduction compared to when receiving ixekizumab.Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and…

Read more